pre-IPO PHARMA

COMPANY OVERVIEW

Tactiva Therapeutics is fighting cancer by developing “Next Generation” adoptive cell therapy (ACT) strategies that deliver lethal hits to cancer cells. Their approach provides robust and sustained immune attack on tumors by infusing large numbers of patients’ own T cells that have been re-programed to recognize, attack and destroy cancer cells.


LOCATION

  • Buffalo, NY, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://tactivatherapeutics.com/


    CAREER WEBSITE

    https://tactivatherapeutics.com/careers/


    SOCIAL MEDIA


    INVESTORS

    efung-capital panacea-ventures vi-ventures


    PRESS RELEASES


    Dec 3, 2018

    Tactiva Therapeutics Secures $35 Million Series A Financing to Pursue Clinical Development of DEACT Platform


    Nov 26, 2018

    Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer


    Oct 18, 2018

    Tactiva Therapeutics Co-Founder Kunle Odunsi Elected to National Academy of Medicine


    Dec 14, 2017

    Tactiva Therapeutics to Present at Biotech Showcase 2018


    Aug 31, 2017

    Tactiva Therapeutics to Present Positive Data on Novel Dual CD4/CD8 T Cell Receptor in Preclinical Models of Cancer at BioCentury's 24th Annual Newsmakers Conference


    For More Press Releases


    Google Analytics Alternative